文献速递骨软组织肉瘤与黑色素瘤

辅助干扰素-α治疗高危黑色素瘤:个体患者数据荟萃分析

Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis.
PubMed 文献 · Eur J Cancer · 2017-07-07

该个体患者数据荟萃分析纳入15项随机试验(其中11项提供个体患者数据),比较辅助干扰素-α与不用干扰素-α治疗高危黑色素瘤。干扰素-α显著改善无事件生存(HR=0.86,CI 0.81-0.91;P<0.00001)和总生存(HR=0.90,CI 0.85-0.97;P=0.003)。仅溃疡型肿瘤患者似乎获益,无溃疡者未见获益,需进一步研究。

要点

  • 辅助干扰素-α显著改善高危黑色素瘤的无事件生存(HR=0.86)。
  • 辅助干扰素-α显著改善总生存(HR=0.90)。
  • 仅溃疡型肿瘤患者似乎获益,无溃疡者未见获益。

核心结论

  • 该荟萃分析提供明确证据表明辅助干扰素-α显著降低复发风险并改善生存,且较高剂量与较低剂量相比未显示额外获益。
  • 溃疡型肿瘤患者获益增加而无溃疡患者未见获益,需进一步研究。

研究设计与样本

  • 研究为个体患者数据荟萃分析,纳入所有辅助干扰素-α对比不用干扰素-α治疗高危黑色素瘤的随机试验。
  • 共纳入15项试验,其中11项提供个体患者数据。
  • 主要结局为无事件生存和总生存,采用标准定量个体患者数据荟萃分析方法。
  • 按剂量、治疗持续时间及各种患者和疾病特异性参数进行亚组分析。

主要发现

  • 干扰素-α显著改善无事件生存(HR=0.86,CI 0.81-0.91;P<0.00001)。
  • 干扰素-α显著改善总生存(HR=0.90,CI 0.85-0.97;P=0.003)。
  • 5年和10年无事件生存绝对差异分别为3.5%和2.7%,总生存绝对差异分别为3.0%和2.8%,均有利于干扰素-α。
  • 无证据表明干扰素-α的获益因剂量、治疗持续时间、年龄、性别、原发肿瘤部位、疾病分期、Breslow厚度或临床淋巴结状态而异。
  • 仅溃疡存在交互作用证据(无事件生存异质性检验P=0.04;总生存异质性检验P=0.002);仅溃疡型肿瘤患者似乎从干扰素-α获益。

关键数值与推荐

  • 无事件生存:HR=0.86,CI 0.81-0.91;P<0.00001。
  • 总生存:HR=0.90,CI 0.85-0.97;P=0.003。
  • 5年和10年无事件生存绝对差异分别为3.5%和2.7%,总生存绝对差异分别为3.0%和2.8%,均有利于干扰素-α。
  • 溃疡交互作用:无事件生存异质性检验P=0.04;总生存异质性检验P=0.002。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 溃疡型肿瘤患者获益增加而无溃疡患者未见获益,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Many randomised trials assessing interferon-α (IFN-α) as adjuvant therapy for high-risk malignant melanoma have been undertaken. To better assess the role of IFN-α, an individual patient data (IPD) meta-analysis of these trials was undertaken. METHODS: IPD was sought from all randomised trials of adjuvant IFN-α versus no IFN-α for high-risk melanoma. Primary outcomes were event-free survival (EFS) and overall survival (OS). Standard methods for quantitative IPD meta-analysis were used. Subgroup analyses by dose, duration of treatment and various patient and disease-specific parameters were performed. FINDINGS: Fifteen trials were included in the analysis (eleven with IPD). EFS was significantly improved with IFN-α (hazard ratio [HR] = 0.86, CI 0.81-0.91; P < 0.00001), as was OS (HR = 0.90, CI 0.85-0.97; P = 0.003). The absolute differences in EFS at 5 and 10 years were 3.5% and 2.7%, and for OS were 3.0% and 2.8% respectively in favour of IFN-α. There was no evidence that the benefit of IFN-α differed depending on dose or duration of treatment, or by age, gender, site of primary tumour, disease stage, Breslow thickness, or presence of clinical nodes. Only for ulceration was there evidence of an interaction (test for heterogeneity: P = 0.04 for EFS; P = 0.002 for OS); only patients with ulcerated tumours appeared to obtain benefit from IFN-α. CONCLUSION: This meta-analysis provides clear evidence that adjuvant IFN-α significantly reduces the risk of relapse and improves survival and shows no benefit for higher doses compared to lower doses. The increased benefit in patients with ulcerated tumours, and lack of benefit in patients without ulceration, needs further investigation.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ives NJ, Suciu S, Eggermont AMM, et al. Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis. Eur J Cancer. 2017. PMID: 28692949. doi:10.1016/j.ejca.2017.06.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。